EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics

Samradhi Singh iD, Namrata Pal, Swasti Shubham, Devojit Kumar Sarma iD, Vinod Verma, Francesco Marotta, Manoj Kumar iD

Journal of Clinical Medicine · 11.02.2023 · 12 (4) · 1454

DOI: 10.3390/jcm12041454 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.02.2023. Verfasst von Samradhi Singh und 6 weiteren Autor:innen. Beteiligte Einrichtung: ICMR-National Institute for Research in Environmental Health, Bhopal Bypass Road, Bhopal 462030, India. Die Arbeit wurde bisher 499-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, typically characterized by anovulation, infertility, obesity, insulin resistance, and polycystic ovaries. Lifestyle or diet, environmental pollutants, genetics, gut dysbiosis, neuroendocrine alterations, and obesity are among the risk factors that predispose females to PCOS. These factors might contribute to upsurging metabolic syndrome by causing hyperinsulinemia, oxidative stress, hyperandrogenism, impaired folliculogenesis, and irregular menstrual cycles. Dysbiosis of gut microbiota may play a pathogenic role in the development of PCOS. The restoration of gut microbiota by probiotics, prebiotics, or a fecal microbiota transplant (FMT) might serve as an innovative, efficient, and noninvasive way to prevent and mitigate PCOS. This review deliberates on the variety of risk factors potentially involved in the etiology, prevalence, and modulation of PCOS, in addition to plausible therapeutic interventions, including miRNA therapy and the eubiosis of gut microbiota, that may help treat and manage PCOS.

Schlagwörter

Stichwörter der Autor:innen

FMTPCOSgut dysbiosisgut microbiomehyperandrogenismhyperinsulinemiametabolic disordersmiRNA therapyprobiotics

Autor:innen und Institutionen

  • ICMR-National Institute for Research in Environmental Health, Bhopal Bypass Road, Bhopal 462030, India.
  • Stem Cell Research Centre, Department of Hematology, Sanjay Gandhi Post-Graduate Institute of MedicalSciences, Lucknow 226014, India.
  • ReGenera R&D International for Aging Intervention, 20144 Milano, Lombardia, Italy.

ORCID-Profile: Samradhi Singh, Devojit Kumar Sarma, Manoj Kumar

Zitieren

APA

Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023). Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. Journal of Clinical Medicine, 12(4), 1454. https://doi.org/10.3390/jcm12041454

Vancouver

Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. Journal of Clinical Medicine. 2023;12(4):1454. doi:10.3390/jcm12041454

BibTeX
@article{Singh2023,
  author = {Singh, Samradhi and Pal, Namrata and Shubham, Swasti and Sarma, Devojit Kumar and Verma, Vinod and Marotta, Francesco and Kumar, Manoj},
  title = {Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {1454},
  doi = {10.3390/jcm12041454}
}
Kostenlos starten →